RxDoctor Payments Data

Sherine Browne

Adult Health · White Plains, NYNPI 1376887950

Payments from drug & device makers

$889in general payments, 2019–2025

Across 28 payments — averaging $31.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$409
  • GSK$167
  • AstraZeneca$95
  • Astellas Pharma US Inc$49
  • Johnson & Johnson$34
  • Lilly USA, LLC$31
  • plus $104 from 5 others

What the payments were for

  • Food & beverage$889100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$889 in reported general payments places this provider in the 65th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$41,488
Medicare patients
77
Services billed
564

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala34$145,706
GenvoyaElviteg/Cob/Emtri/Tenof Alafen15$63,612
TivicayDolutegravir Sodium22$51,717
OzempicSemaglutide39$41,776
DescovyEmtricitabine/Tenofov Alafenam16$37,240
EdurantRilpivirine Hcl23$36,464
JardianceEmpagliflozin76$26,104
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate12$24,730
TrulicityDulaglutide12$21,128
EliquisApixaban66$20,050
PrezcobixDarunavir/Cobicistat12$16,135
FarxigaDapagliflozin Propanediol30$8,480
MyrbetriqMirabegron29$6,705
Lamivudine HbvLamivudine18$6,566
JanuviaSitagliptin Phosphate14$6,305

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyTivicay$21$51,71722 claims
Novo NordiskOzempic$409$41,77639 claims
Lilly USA, LLCTrulicity$31$21,12812 claims
Johnson & JohnsonPrezcobix$34$16,13512 claims
AstraZenecaFarxiga$95$8,48030 claims
Astellas Pharma US IncMyrbetriq$49$6,70529 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,828 adult health providers in New York.

Other adult health in White Plains

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →